Denise Jen

Practice Areas

-Mergers and Acquisitions

-Cross-border Investment

-Private Equity Fund

-Capital Markets

-Energy

-General Corporate and Securities Laws

-Biotech and Pharmaceutical Laws

-Compliance

Professional Memberships

Admitted in Taiwan

Admitted in New York, U.S.A

Certificate of Family Trust Planning Consultant

Publications

- M&A Taiwan section (Lexology Getting the Deal Through Market Intelligence)

- Corporate M&A – Taiwan: Trends and Developments (Chambers Global Practice Guide)

- Acquisition Finance Taiwan section (Lexology Getting the Deal Through)

- Private Equity Taiwan section (Lexology in-depth)

- “Digit and Innovation: Intellectual Property Law Issues under the Open Banking Regime” (The Changing Fintech Laws by LCS Elites)

- “The Legal Challenge from Sharing Economy to Sharing Finance” (Fintech Development and Laws by LCS Elites)

- “The Prospect and Limitation of Fundraising Activities for Biotech Industries in Taiwan” (Legal Practice and Operation of Modern Businesses by LCS Elites)

- "Negotiation of Cross-Border Brand Licensing" (Business Law Commentary by LCS Elites)

- "Merger and Acquisition of REITs" (Trust Association)

- "Responsibilities of the trust enterprise, in its role as a trustee, acting as the proprietor of a building and recommendations" (Trust Association)

- "Fairness Test on Corporate Director's Self-Dealing: An Analysis of the Case of Weinberger v. UOP and Further Issues" (Cross-Strait Law Review)

Personal

Denise Jen is a partner of LCS & Partners. Her practice focuses on public and private mergers and acquisitions, joint ventures, private equity and venture capital, banking and finance, energy, and multi-jurisdiction transactions of all types. Her clients include companies from the high-tech industry, pharmaceutical and biotech industries, and start-ups and venture capital funds. Denise also frequently advises clients on regulatory compliance, civil and commercial laws and corporate governance matters. She has recently successfully represented multiple clients in the biotech and pharmaceutical industry in M&A exit and fundraising transactions.

Denise has been consecutively recognized as a Rising Star Partner by IFLR (International Financial Law Review) since 2022 and listed as Up-and-Coming in the Corporate M&A section by Chambers and Partners since 2023.

Work Highlights

-Representation of TXOne Network in its multi-series preferred shares fund raising and corporate restructuring.

-Representation of Bora Pharmaceutical in the US$50M acquisition of Eden Biologics’ CDMO businesses and US$195M acquisition of 100% equity stake of TWi Pharmaceuticals.

-Representation of MagiCapital in the US$138M acquisition of Ili Technology (a 100% subsidiary of MediaTek).

-Representation of Quaser Group (a Taiwan listed company) of its acquisition of Winbro Group (a US and UK company in aerospace industry) and obtain US CFIUS approval.

-Representation of TPG Group’s acquisition of OPC Group (the top one CRO company in Taiwan).

-Representation of Guangdong Fenghua Advanced Technology (a Shenzhen listed company) in its tender offer of Viking Tech. (First tender offer deal of a Taiwan listed company by a PRC investor).

-Representation of CID -led consortium in its tender offer and merger of Entire Technology and APEC (both are Taiwan listed companies).

-Representation of Bora Pharmaceutical’s acquisition of 100% shareholding in Impax Laboratories (a subsidiary of US Impax group) and various investment projects.

-Representation of JEAN Group (a Taiwan listed company) in its asset sale to BOE Group (a Chinese SOE).

-Representation of Novartis in its transaction with GlaxoSmithKline (“GSK”) in the sale of Novartis’ non-influenza Vaccines business and acquisition of GSK’s oncology portfolio.

-Representation of overseas Taiwanese investment in acquisition of targets in Europe, America and Asia.

-Offshore PE fund formation in the form of limited partnership and segregated portfolio company (AI, real property, manufacturing, IOT industry and etc.) and subsequent fund investment.

-Taiwan PE fund formation in the form of closed-end company and limited partnership (biotech, pharmaceutical, manufacturing, IT semiconductor, energy and etc.) and subsequent fund investment.

-Representation of Venture Capital companies in their investment and disposal of portfolio companies.

-Representation of pharmaceutical companies and biotech companies in their clinical trial, OEM, license agreement and co-development of pharmaceutical products with various business partners.

-Representation of foreign investors and domestic private equity firms in the formation of energy funds and subsequent investments in solar energy projects.

-Representation of IPO projects in Hong Kong Stock Exchange, Shanghai Stock Exchange and Taiwan Stock Exchange.

Education

Awards